Doycheva, Deshka and Jaegle, Herbert and Zierhut, Manfred and Deuter, Christoph and Blumenstock, Gunnar and Schiefer, Ulrich and Stingl, Katarina and Januschowski, Kai and Voykov, Bogomil and Stuebiger, Nicole (2015) Mycophenolic acid in the treatment of birdshot chorioretinopathy: long-term follow-up. BRITISH JOURNAL OF OPHTHALMOLOGY, 99 (1). pp. 87-91. ISSN 0007-1161, 1468-2079
Full text not available from this repository. (Request a copy)Abstract
Aim To assess the long-term efficacy and tolerability of both derivatives of mycophenolic acid, mycophenolate mofetil (MMF) and mycophenolate sodium (MPS), in the therapy of patients with birdshot chorioretinopathy (BSCR). Methods Retrospective analysis of 24 patients (48 eyes) with BSCR, treated with MMF or MPS with a follow-up of at least 1 year. The main outcome measures included control of inflammation, steroid-sparing potential and side effects. Secondary outcome measure was the development of retinal function during the therapy measured by best-corrected visual acuity (BCVA), visual field and/or electroretinography (ERG). Results Twelve patients (50%) were treated with MMF and 12 patients (50%) with MPS. Control of intraocular inflammation, defined as complete lack of clinical and angiographic signs of inflammatory activity, was achieved in 16 of 24 patients (67%). The angiographic signs of activity were significantly reduced during the follow-up (p<0.05). No significant difference was found in the mean BCVA, the visual field and the ERG parameters during the treatment compared with the baseline (p>0.05). In 20 out of 21 patients (95%) who received systemic corticosteroids, the corticosteroids could be tapered to a daily dose of <= 10 mg (rate 0.26/patient-year). Drug-related side effects occurred in 12 patients (50%, rate 0.16/patient-year). In four patients (17%), a therapy switch from MMF to MPS was undertaken due to gastrointestinal discomfort. Conclusions Derivatives of mycophenolic acid are effective and safe drugs for the treatment of BSCR. In cases with gastrointestinal side effects, a therapy switch from MMF to MPS should be considered.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | MOFETIL; THERAPY; UVEITIS; RETINOCHOROIDOPATHY; STANDARDIZATION; DISEASE; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Augenheilkunde |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 05 Aug 2019 07:12 |
| Last Modified: | 05 Aug 2019 07:12 |
| URI: | https://pred.uni-regensburg.de/id/eprint/6371 |
Actions (login required)
 |
View Item |
